Rival BTK degraders face off in CLL patients naive to BTK inhibition.
ApexOnco Front Page
Recent articles
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
MK-6837, just like saci-T, is a TROP2-directed ADC, it has emerged.
The industry’s first ALK degrader starts its first human study.
The latest Chinese pivotal study of iza-bren will be in first-line small-cell lung cancer.
AbbVie’s PD-1 x VEGF agreement with RemeGen was the first-quarter’s biggest.
A $3.15bn deal follows a December 2024 option agreement.
The groups spend big on Terns and Arcellx.
